atazanavir ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
HIV protease inhibitors 254 198904-31-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • BMS-232632
  • atazanavir
  • reyataz
  • atazanavir sulphate
  • atazanavir sulfate
An azapeptide and HIV-PROTEASE INHIBITOR that is used in the treatment of HIV INFECTIONS and AIDS in combination with other ANTI-HIV AGENTS. There was some evidence of in vitro activity against SARS-CoV-2, but no clinical trial data was found to support use in the treatment of COVID-19.
  • Molecular weight: 704.87
  • Formula: C38H52N6O7
  • CLOGP: 5.92
  • LIPINSKI: 3
  • HAC: 13
  • HDO: 5
  • TPSA: 171.22
  • ALOGS: -5.33
  • ROTB: 18

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.30 g O
0.30 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 7 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 8.11 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 64 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
March 2, 2004 EMA
June 20, 2003 FDA BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Abortion spontaneous 977.41 26.35 336 8164 41436 50555188
Foetal exposure during pregnancy 863.29 26.35 276 8224 27083 50569541
Maternal exposure during pregnancy 762.91 26.35 417 8083 159361 50437263
Exposure during pregnancy 489.39 26.35 284 8216 120731 50475893
Abortion induced 402.81 26.35 120 8380 9224 50587400
Premature baby 345.60 26.35 126 8374 18211 50578413
Live birth 336.41 26.35 120 8380 16288 50580336
Stillbirth 276.35 26.35 81 8419 5871 50590753
Pregnancy 258.33 26.35 117 8383 29460 50567164
Caesarean section 245.41 26.35 94 8406 15545 50581079
Hyperbilirubinaemia 242.42 26.35 82 8418 9488 50587136
Premature delivery 230.29 26.35 101 8399 23562 50573062
Drug interaction 162.42 26.35 183 8317 199438 50397186
Foetal death 149.47 26.35 55 8445 8125 50588499
Foetal growth restriction 122.70 26.35 45 8455 6582 50590042
Pregnancy on contraceptive 119.14 26.35 29 8471 1023 50595601
Normal newborn 118.60 26.35 44 8456 6647 50589977
Virologic failure 117.21 26.35 31 8469 1533 50595091
Congenital naevus 109.29 26.35 20 8480 166 50596458
Ventricular septal defect 103.75 26.35 35 8465 4006 50592618
Renal colic 100.40 26.35 26 8474 1183 50595441
Viral mutation identified 97.30 26.35 27 8473 1602 50595022
Immune reconstitution inflammatory syndrome 96.75 26.35 36 8464 5480 50591144
Viral load increased 96.53 26.35 25 8475 1138 50595486
Jaundice 95.67 26.35 58 8442 26371 50570253
Premature rupture of membranes 95.65 26.35 34 8466 4546 50592078
Cushing's syndrome 94.93 26.35 22 8478 626 50595998
Supernumerary nipple 93.87 26.35 15 8485 48 50596576
Nephrolithiasis 93.00 26.35 63 8437 34630 50561994
Low set ears 89.77 26.35 18 8482 252 50596372
Acoustic stimulation tests abnormal 87.56 26.35 15 8485 81 50596543
Low birth weight baby 76.88 26.35 31 8469 5850 50590774
Drug ineffective 76.08 26.35 22 8478 819311 49777313
Congenital hydrocephalus 75.29 26.35 14 8486 128 50596496
Lipodystrophy acquired 74.67 26.35 21 8479 1308 50595316
Spina bifida 72.77 26.35 18 8482 679 50595945
Blood bilirubin increased 69.20 26.35 51 8449 31987 50564637
Twin pregnancy 69.01 26.35 19 8481 1094 50595530
Pre-eclampsia 64.41 26.35 30 8470 8014 50588610
Polydactyly 64.34 26.35 14 8486 297 50596327
Patent ductus arteriosus 63.60 26.35 24 8476 3796 50592828
Trisomy 18 63.58 26.35 10 8490 28 50596596
Placenta praevia 62.61 26.35 17 8483 929 50595695
Placental insufficiency 61.92 26.35 18 8482 1263 50595361
Adrenal suppression 59.26 26.35 16 8484 856 50595768
Blood bilirubin unconjugated increased 58.53 26.35 13 8487 304 50596320
Pain 58.50 26.35 13 8487 578890 50017734
Gestational diabetes 57.17 26.35 27 8473 7438 50589186
Drug resistance 52.09 26.35 35 8465 18954 50577670
Premature labour 51.59 26.35 29 8471 11447 50585177
Pathogen resistance 51.15 26.35 23 8477 5666 50590958
Trisomy 21 50.94 26.35 12 8488 367 50596257
Oligohydramnios 50.91 26.35 23 8477 5727 50590897
Fanconi syndrome acquired 49.21 26.35 14 8486 909 50595715
CD4 lymphocytes decreased 48.24 26.35 15 8485 1324 50595300
Renal tubular disorder 46.78 26.35 17 8483 2420 50594204
Polyhydramnios 45.97 26.35 16 8484 2009 50594615
Macrocephaly 45.56 26.35 8 8492 51 50596573
Osteonecrosis 42.32 26.35 33 8467 22484 50574140
Congenital central nervous system anomaly 41.92 26.35 10 8490 323 50596301
Hydrocephalus 41.91 26.35 19 8481 4769 50591855
Blood HIV RNA increased 41.70 26.35 11 8489 538 50596086
Fatigue 41.48 26.35 35 8465 707566 49889058
Foetal distress syndrome 40.91 26.35 13 8487 1232 50595392
Ultrasound antenatal screen abnormal 39.57 26.35 8 8492 117 50596507
Left ventricular dilatation 39.43 26.35 10 8490 418 50596206
Fall 39.31 26.35 5 8495 334927 50261697
Eosinophilia 38.71 26.35 29 8471 18623 50578001
Microcephaly 37.38 26.35 11 8489 805 50595819
Coarctation of the aorta 36.54 26.35 10 8490 563 50596061
Ectopic pregnancy 36.50 26.35 14 8486 2313 50594311
Breast disorder 34.73 26.35 13 8487 2009 50594615
Dyspnoea 34.68 26.35 25 8475 547583 50049041
Mitochondrial cytopathy 34.54 26.35 8 8492 227 50596397
Ocular icterus 34.29 26.35 15 8485 3460 50593164
Amniotic cavity infection 33.54 26.35 11 8489 1152 50595472
Hepatic cytolysis 32.47 26.35 19 8481 8084 50588540
Alpha 1 foetoprotein abnormal 32.35 26.35 6 8494 54 50596570
Calculus urinary 31.57 26.35 10 8490 938 50595686
Hepatitis 30.96 26.35 32 8468 31421 50565203
Congenital anomaly 30.65 26.35 11 8489 1510 50595114
Joint swelling 30.43 26.35 3 8497 245283 50351341
Encephalomalacia 29.39 26.35 8 8492 441 50596183
Congenital genital malformation female 29.34 26.35 5 8495 26 50596598
Maternal drugs affecting foetus 28.87 26.35 15 8485 5062 50591562
Foetal anaemia 28.74 26.35 5 8495 30 50596594
Isoimmune haemolytic disease 28.60 26.35 5 8495 31 50596593
Epidural lipomatosis 28.56 26.35 6 8494 107 50596517
Conduction disorder 28.41 26.35 10 8490 1298 50595326
Oesophageal atresia 28.12 26.35 8 8492 519 50596105
Congenital skin dimples 28.10 26.35 6 8494 116 50596508
Placental chorioangioma 28.00 26.35 4 8496 4 50596620
Subchorionic haematoma 27.77 26.35 6 8494 123 50596501
Cerebral ventricle dilatation 27.58 26.35 9 8491 928 50595696
Placental disorder 27.54 26.35 10 8490 1420 50595204

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 1247.28 17.38 927 14292 196458 29362850
Depression 1159.11 17.38 650 14569 84497 29474811
Nephrolithiasis 453.44 17.38 233 14986 25101 29534207
Hyperbilirubinaemia 399.50 17.38 181 15038 14753 29544555
Foetal exposure during pregnancy 379.73 17.38 229 14990 33638 29525670
Lipodystrophy acquired 370.64 17.38 113 15106 2981 29556327
Renal colic 333.28 17.38 90 15129 1515 29557793
Jaundice 252.88 17.38 168 15051 29128 29530180
Loss of personal independence in daily activities 239.36 17.38 154 15065 25286 29534022
Renal tubular disorder 212.09 17.38 81 15138 4271 29555037
Blood bilirubin increased 167.44 17.38 139 15080 33754 29525554
Mitochondrial toxicity 166.34 17.38 58 15161 2353 29556955
Fanconi syndrome acquired 153.28 17.38 51 15168 1791 29557517
Immune reconstitution inflammatory syndrome 148.74 17.38 75 15144 7727 29551581
Eyelid ptosis 123.34 17.38 58 15161 5128 29554180
Psychiatric decompensation 122.59 17.38 41 15178 1463 29557845
Depression suicidal 119.84 17.38 39 15180 1276 29558032
Calculus urinary 116.62 17.38 37 15182 1114 29558194
Tearfulness 111.48 17.38 39 15180 1597 29557711
Ocular icterus 103.91 17.38 42 15177 2573 29556735
Virologic failure 100.46 17.38 42 15177 2805 29556503
Lipoatrophy 90.24 17.38 25 15194 464 29558844
Blood bilirubin unconjugated increased 86.93 17.38 25 15194 534 29558774
HIV-associated neurocognitive disorder 85.94 17.38 22 15197 297 29559011
Viral load increased 85.19 17.38 34 15185 2015 29557293
Blood HIV RNA increased 79.84 17.38 27 15192 997 29558311
Osteonecrosis 78.49 17.38 61 15158 13458 29545850
Fanconi syndrome 75.17 17.38 29 15190 1569 29557739
Premature baby 73.29 17.38 65 15154 17215 29542093
Heterotaxia 72.46 17.38 16 15203 108 29559200
Trisomy 21 71.43 17.38 21 15198 486 29558822
Proteinuria 70.14 17.38 61 15158 15743 29543565
Cushing's syndrome 67.15 17.38 19 15200 382 29558926
Depressive symptom 66.24 17.38 27 15192 1690 29557618
Diplopia 65.76 17.38 55 15164 13463 29545845
CD4 lymphocytes decreased 64.64 17.38 26 15193 1572 29557736
Death 63.63 17.38 50 15169 342034 29217274
Single umbilical artery 63.56 17.38 16 15203 201 29559107
Cholelithiasis 61.44 17.38 61 15158 18611 29540697
Osteoporosis 61.23 17.38 48 15171 10721 29548587
Paranoia 60.47 17.38 46 15173 9831 29549477
Kaposi's sarcoma 60.46 17.38 21 15198 841 29558467
Glycosuria 57.93 17.38 22 15197 1140 29558168
Viral mutation identified 56.62 17.38 27 15192 2461 29556847
Psychomotor skills impaired 54.89 17.38 27 15192 2634 29556674
Psychotic disorder 51.82 17.38 58 15161 20296 29539012
Cortisol decreased 49.76 17.38 18 15201 813 29558495
Hypotension 49.67 17.38 19 15200 194335 29364973
Suicidal ideation 49.14 17.38 74 15145 34642 29524666
Nephropathy toxic 48.70 17.38 42 15177 10714 29548594
Ureterolithiasis 48.17 17.38 22 15197 1818 29557490
Drug ineffective 46.65 17.38 72 15147 363098 29196210
Hypertriglyceridaemia 43.97 17.38 34 15185 7441 29551867
Blood antidiuretic hormone increased 42.73 17.38 9 15210 47 29559261
Chordee 40.99 17.38 9 15210 59 29559249
Nephrocalcinosis 40.88 17.38 14 15205 537 29558771
Vanishing bile duct syndrome 39.99 17.38 14 15205 574 29558734
Hypophosphataemia 38.03 17.38 32 15187 7892 29551416
Drug resistance 37.98 17.38 51 15168 21489 29537819
Off label use 37.28 17.38 61 15158 300739 29258569
Fall 36.65 17.38 23 15196 177155 29382153
Pneumonia 35.14 17.38 70 15149 320102 29239206
Neonatal hyponatraemia 34.30 17.38 8 15211 71 29559237
Exposure during pregnancy 33.94 17.38 31 15188 8523 29550785
Adrenal suppression 33.64 17.38 12 15207 520 29558788
HIV wasting syndrome 33.00 17.38 8 15211 85 29559223
Congenital hydrocephalus 32.83 17.38 8 15211 87 29559221
Febrile neutropenia 32.11 17.38 9 15210 112231 29447077
Pathogen resistance 31.39 17.38 29 15190 8087 29551221
Dyspnoea 31.28 17.38 77 15142 326655 29232653
Congenital naevus 31.13 17.38 6 15213 18 29559290
Hepatitis C 30.96 17.38 30 15189 8880 29550428
Hepatitis 30.39 17.38 45 15174 20738 29538570
Psychomotor retardation 30.39 17.38 19 15200 2957 29556351
Enanthema 30.05 17.38 10 15209 351 29558957
Hepatic cirrhosis 29.85 17.38 37 15182 14407 29544901
Hypothalamic pituitary adrenal axis suppression 29.53 17.38 8 15211 136 29559172
Dysphagia 29.52 17.38 78 15141 54848 29504460
Crystal urine 29.08 17.38 7 15212 72 29559236
Anomalous pulmonary venous connection 28.91 17.38 7 15212 74 29559234
Disease progression 28.78 17.38 4 15215 81912 29477396
CSF virus identified 28.70 17.38 6 15213 30 29559278
Low birth weight baby 28.29 17.38 25 15194 6583 29552725
Completed suicide 28.22 17.38 6 15213 90240 29469068
Hydronephrosis 27.75 17.38 28 15191 8702 29550606
Biliary colic 27.61 17.38 12 15207 881 29558427
CSF HIV escape syndrome 27.50 17.38 8 15211 178 29559130
Trimethylaminuria 27.38 17.38 5 15214 10 29559298
Haemophilic arthropathy 26.66 17.38 7 15212 105 29559203
Alpha 1 foetoprotein abnormal 26.20 17.38 5 15214 14 29559294
Alanine aminotransferase increased 26.02 17.38 88 15131 70856 29488452
Renal failure 25.78 17.38 125 15094 118474 29440834
Tubulointerstitial nephritis 25.51 17.38 38 15181 17605 29541703
Jarisch-Herxheimer reaction 25.48 17.38 9 15210 379 29558929
Hepatic cytolysis 25.13 17.38 26 15193 8321 29550987
Cardiac failure congestive 24.13 17.38 5 15214 76576 29482732
Intestinal malrotation 23.92 17.38 5 15214 25 29559283
Persistent left superior vena cava 23.52 17.38 4 15215 4 29559304
Hyperadrenocorticism 23.50 17.38 6 15213 80 29559228
Blood pressure increased 22.88 17.38 5 15214 73798 29485510
Umbilical cord abnormality 21.79 17.38 5 15214 41 29559267
Heart transplant rejection 21.73 17.38 11 15208 1140 29558168
Renal tubular dysfunction 21.24 17.38 8 15211 405 29558903
Foetal chromosome abnormality 21.01 17.38 4 15215 11 29559297
Acquired immunodeficiency syndrome 20.98 17.38 8 15211 419 29558889
Hyperlipidaemia 20.96 17.38 29 15190 12561 29546747
Constipation 20.72 17.38 17 15202 114143 29445165
Ventricular septal defect 20.64 17.38 16 15203 3513 29555795
Sepsis 20.51 17.38 26 15193 142656 29416652
Wrong dose 20.37 17.38 8 15211 454 29558854
Acute stress disorder 20.32 17.38 6 15213 141 29559167
Adrenogenital syndrome 20.31 17.38 5 15214 57 29559251
Facial wasting 20.16 17.38 6 15213 145 29559163
Atrial fibrillation 20.10 17.38 15 15204 105631 29453677
Drug abuse 20.05 17.38 8 15211 79875 29479433
Cardiac failure 19.80 17.38 8 15211 79279 29480029
Drug level increased 19.72 17.38 35 15184 18752 29540556
Foetal monitoring abnormal 19.72 17.38 3 15216 0 29559308
Pancreatitis 19.55 17.38 50 15169 34464 29524844
Portal fibrosis 19.39 17.38 7 15212 314 29558994
Encephalitis 19.30 17.38 20 15199 6410 29552898
Right aortic arch 19.13 17.38 4 15215 20 29559288
Mitochondrial cytopathy 19.09 17.38 6 15213 175 29559133
Encephalitis viral 19.02 17.38 10 15209 1122 29558186
Congenital hepatomegaly 18.97 17.38 4 15215 21 29559287
Anogenital warts 18.81 17.38 8 15211 557 29558751
Infection 18.76 17.38 8 15211 76743 29482565
Anal cancer 18.54 17.38 7 15212 357 29558951
Myoglobin blood increased 18.53 17.38 12 15207 1983 29557325
Erythema elevatum diutinum 18.38 17.38 4 15215 25 29559283
Thalassaemia alpha 18.38 17.38 4 15215 25 29559283
Genitalia external ambiguous 18.13 17.38 6 15213 207 29559101
Deafness congenital 18.03 17.38 5 15214 93 29559215
Renal impairment 17.85 17.38 86 15133 81247 29478061
Foetal cystic hygroma 17.64 17.38 3 15216 3 29559305
Polymicrogyria 17.64 17.38 3 15216 3 29559305
Nasal septum deviation 17.63 17.38 9 15210 950 29558358
Aspartate aminotransferase increased 17.59 17.38 69 15150 59656 29499652

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 1162.62 17.70 887 17018 361196 64119631
Abortion spontaneous 856.55 17.70 305 17600 24838 64455989
Depression 683.01 17.70 493 17412 182798 64298029
Maternal exposure during pregnancy 563.20 17.70 343 17562 95541 64385286
Hyperbilirubinaemia 562.07 17.70 214 17691 20991 64459836
Lipodystrophy acquired 475.62 17.70 127 17778 3900 64476927
Nephrolithiasis 463.23 17.70 231 17674 43452 64437375
Abortion induced 317.43 17.70 103 17802 6285 64474542
Jaundice 314.01 17.70 185 17720 48327 64432500
Renal colic 305.50 17.70 80 17825 2272 64478555
Exposure during pregnancy 279.18 17.70 205 17700 77470 64403357
Stillbirth 240.74 17.70 73 17832 3560 64477267
Immune reconstitution inflammatory syndrome 233.35 17.70 98 17807 12372 64468455
Renal tubular disorder 220.18 17.70 77 17828 5910 64474917
Mitochondrial toxicity 208.07 17.70 61 17844 2645 64478182
Live birth 199.47 17.70 85 17820 11119 64469708
Blood bilirubin increased 186.84 17.70 143 17762 57410 64423417
Pregnancy 176.77 17.70 95 17810 20770 64460057
Caesarean section 176.12 17.70 78 17827 11196 64469631
Fanconi syndrome acquired 174.87 17.70 52 17853 2369 64478458
Premature delivery 172.65 17.70 90 17815 18499 64462328
Viral mutation identified 170.47 17.70 55 17850 3291 64477536
Loss of personal independence in daily activities 169.96 17.70 149 17756 72305 64408522
Viral load increased 160.61 17.70 49 17856 2438 64478389
Virologic failure 156.51 17.70 52 17853 3414 64477413
Calculus urinary 134.62 17.70 40 17865 1817 64479010
Blood bilirubin unconjugated increased 132.70 17.70 34 17871 883 64479944
Psychiatric decompensation 131.68 17.70 42 17863 2421 64478406
Eyelid ptosis 126.94 17.70 59 17846 9466 64471361
Cushing's syndrome 126.63 17.70 33 17872 918 64479909
Depression suicidal 119.25 17.70 39 17866 2436 64478391
Foetal death 115.60 17.70 48 17857 5882 64474945
Pregnancy on contraceptive 107.99 17.70 28 17877 763 64480064
Osteonecrosis 104.64 17.70 76 17829 28153 64452674
Ocular icterus 101.86 17.70 42 17863 5056 64475771
Tearfulness 98.49 17.70 40 17865 4633 64476194
Pathogen resistance 94.85 17.70 53 17852 12490 64468337
Adrenal suppression 93.65 17.70 28 17877 1299 64479528
CD4 lymphocytes decreased 92.14 17.70 32 17873 2403 64478424
Fanconi syndrome 91.30 17.70 32 17873 2469 64478358
Drug resistance 85.89 17.70 74 17831 35028 64445799
Normal newborn 81.76 17.70 37 17868 5580 64475247
CSF HIV escape syndrome 77.43 17.70 18 17887 307 64480520
HIV-associated neurocognitive disorder 77.37 17.70 18 17887 308 64480519
Proteinuria 77.24 17.70 63 17842 27660 64453167
Blood HIV RNA increased 73.99 17.70 24 17881 1460 64479367
Drug ineffective 72.73 17.70 76 17829 840171 63640656
Foetal exposure during pregnancy 69.99 17.70 31 17874 4445 64476382
Paranoia 69.80 17.70 48 17857 16304 64464523
Psychomotor skills impaired 67.85 17.70 29 17876 3816 64477011
Nephropathy toxic 66.82 17.70 48 17857 17466 64463361
Osteoporosis 65.32 17.70 69 17836 42011 64438816
Premature rupture of membranes 65.28 17.70 28 17877 3716 64477111
Lipoatrophy 65.18 17.70 18 17887 627 64480200
Twin pregnancy 64.69 17.70 19 17886 828 64479999
Diplopia 60.60 17.70 54 17851 26711 64454116
Hepatitis 59.09 17.70 68 17837 45514 64435313
Glycosuria 58.74 17.70 22 17883 2052 64478775
Depressive symptom 57.27 17.70 27 17878 4469 64476358
Cortisol decreased 55.68 17.70 20 17885 1657 64479170
Hypertriglyceridaemia 55.30 17.70 36 17869 11169 64469658
Placenta praevia 54.64 17.70 16 17889 690 64480137
Fall 54.20 17.70 24 17881 416802 64064025
Pain 53.73 17.70 45 17860 553466 63927361
Pre-eclampsia 51.71 17.70 28 17877 6203 64474624
Psychotic disorder 50.67 17.70 55 17850 34523 64446304
Renal failure 50.55 17.70 137 17768 181551 64299276
Cholelithiasis 49.33 17.70 62 17843 45444 64435383
Hypophosphataemia 46.45 17.70 36 17869 14684 64466143
Renal tubular dysfunction 46.08 17.70 14 17891 686 64480141
Dyspnoea 44.99 17.70 82 17823 718592 63762235
Mitochondrial cytopathy 44.52 17.70 12 17893 381 64480446
Ureterolithiasis 43.18 17.70 20 17885 3181 64477646
Suicidal ideation 43.15 17.70 71 17834 66471 64414356
Hypotension 42.07 17.70 27 17878 380947 64099880
Spina bifida 41.28 17.70 8 17897 53 64480774
Acute kidney injury 40.24 17.70 237 17668 449003 64031824
Polyhydramnios 39.31 17.70 15 17890 1472 64479355
Secondary adrenocortical insufficiency 39.12 17.70 17 17888 2328 64478499
Blood antidiuretic hormone increased 39.02 17.70 8 17897 73 64480754
Death 37.97 17.70 47 17858 482658 63998169
Vanishing bile duct syndrome 37.83 17.70 14 17891 1263 64479564
Placental insufficiency 37.04 17.70 13 17892 1007 64479820
Peripheral swelling 36.33 17.70 7 17898 209146 64271681
Hepatic cytolysis 35.13 17.70 30 17875 14019 64466808
HIV wasting syndrome 34.23 17.70 7 17898 63 64480764
Joint swelling 33.82 17.70 9 17896 215373 64265454
Nephrocalcinosis 33.63 17.70 13 17892 1321 64479506
Hypothalamic pituitary adrenal axis suppression 33.41 17.70 9 17896 285 64480542
Tubulointerstitial nephritis 33.32 17.70 42 17863 30867 64449960
Treatment noncompliance 33.17 17.70 50 17855 43432 64437395
Gestational diabetes 32.69 17.70 20 17885 5570 64475257
Amniotic cavity infection 32.51 17.70 11 17894 763 64480064
Psychomotor retardation 31.62 17.70 19 17886 5124 64475703
CSF virus identified 31.47 17.70 6 17899 36 64480791
Off label use 31.44 17.70 82 17823 632724 63848103
Blood corticotrophin decreased 31.10 17.70 9 17896 372 64480455
Premature baby 30.82 17.70 16 17889 3256 64477571
Infection 30.43 17.70 7 17898 184873 64295954
Abdominal discomfort 29.82 17.70 7 17898 182315 64298512
Ergot poisoning 29.30 17.70 7 17898 135 64480692
Genotype drug resistance test positive 29.29 17.70 11 17894 1033 64479794
Syphilis 29.09 17.70 9 17896 469 64480358
Acute HIV infection 28.68 17.70 6 17899 61 64480766
Swelling 28.59 17.70 5 17900 160213 64320614
Cough 27.52 17.70 26 17879 302122 64178705
Placental disorder 27.48 17.70 10 17895 860 64479967
Constipation 27.05 17.70 15 17890 229322 64251505
Acquired immunodeficiency syndrome 26.13 17.70 7 17898 217 64480610
Placental chorioangioma 25.99 17.70 4 17901 4 64480823
Nasopharyngitis 25.89 17.70 11 17894 196062 64284765
Jarisch-Herxheimer reaction 25.88 17.70 9 17896 678 64480149
Congenital hydrocephalus 25.56 17.70 5 17900 35 64480792
Subchorionic haematoma 25.56 17.70 6 17899 107 64480720
Kaposi's sarcoma 25.12 17.70 9 17896 740 64480087
Crystal urine 25 17.70 6 17899 118 64480709
Alanine aminotransferase increased 24.87 17.70 90 17815 138941 64341886
Pneumonia 24.47 17.70 77 17828 559499 63921328
Dysphagia 24.31 17.70 75 17830 106737 64374090
Cholestasis 24.01 17.70 44 17861 44828 64435999
Toxic skin eruption 23.69 17.70 28 17877 19256 64461571
Conduction disorder 23.69 17.70 13 17892 2955 64477872
Encephalitis viral 23.46 17.70 12 17893 2368 64478459
Alpha 1 foetoprotein abnormal 23.46 17.70 5 17900 56 64480771
Hydronephrosis 23.41 17.70 24 17881 14101 64466726
Completed suicide 23.28 17.70 17 17888 224397 64256430
Cholestasis of pregnancy 23.27 17.70 9 17896 916 64479911
Premature labour 22.66 17.70 18 17887 7602 64473225
Hepatic cirrhosis 22.61 17.70 32 17873 26266 64454561
Erythema elevatum diutinum 22.53 17.70 4 17901 15 64480812
Hepatitis C 22.53 17.70 21 17884 10994 64469833
Febrile neutropenia 22.52 17.70 12 17893 187645 64293182
Urinary tract infection 22.19 17.70 19 17886 231577 64249250
Bilirubin conjugated increased 22.18 17.70 15 17890 4953 64475874
Disease progression 22.08 17.70 6 17899 141674 64339153
Encephalitis 22.01 17.70 22 17883 12549 64468278
Blood creatinine increased 21.88 17.70 85 17820 135697 64345130
Myoglobin blood increased 21.84 17.70 12 17893 2735 64478092
Gynaecomastia 21.83 17.70 16 17889 6000 64474827
Ectopic pregnancy 21.81 17.70 10 17895 1554 64479273
Adrenal insufficiency 21.80 17.70 29 17876 22458 64458369
Enanthema 21.49 17.70 8 17897 733 64480094
Cardiac failure congestive 21.37 17.70 5 17900 130575 64350252
Renal impairment 21.33 17.70 84 17821 134933 64345894
ACTH stimulation test abnormal 21.13 17.70 4 17901 23 64480804
Lipohypertrophy 20.98 17.70 8 17897 784 64480043
Pancreatitis 20.77 17.70 49 17856 59558 64421269
Blood pressure increased 20.76 17.70 11 17894 172541 64308286
Arthralgia 20.65 17.70 59 17846 442201 64038626
Oligohydramnios 20.40 17.70 12 17893 3112 64477715
Seborrhoeic dermatitis 20.33 17.70 10 17895 1816 64479011
Cerebral toxoplasmosis 20.33 17.70 10 17895 1816 64479011
Mycobacterium avium complex infection 20.28 17.70 13 17892 3927 64476900
Placental infarction 20.13 17.70 5 17900 114 64480713
Cytomegalovirus chorioretinitis 19.97 17.70 14 17891 4898 64475929
Product dose omission issue 19.87 17.70 15 17890 194732 64286095
Blood lactic acid increased 19.69 17.70 19 17886 10382 64470445
Portal fibrosis 19.45 17.70 7 17898 583 64480244
Hyperadrenocorticism 19.44 17.70 6 17899 310 64480517
Product use issue 19.26 17.70 9 17896 151706 64329121
Atrial fibrillation 19.02 17.70 12 17893 171077 64309750
Product use in unapproved indication 18.81 17.70 13 17892 176605 64304222
Nasal septum deviation 18.81 17.70 9 17896 1539 64479288
Trimethylaminuria 18.63 17.70 5 17900 156 64480671
Cushingoid 18.53 17.70 16 17889 7587 64473240
Pain in extremity 18.51 17.70 35 17870 303050 64177777
Aspartate aminotransferase increased 18.49 17.70 74 17831 119714 64361113
Renal tubular acidosis 18.30 17.70 11 17894 2968 64477859
Acute stress disorder 18.01 17.70 6 17899 397 64480430

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AE08 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Protease inhibitors
ATC J05AR15 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR23 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
FDA MoA N0000000246 HIV Protease Inhibitors
MeSH PA D019380 Anti-HIV Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D044966 Anti-Retroviral Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D017320 HIV Protease Inhibitors
MeSH PA D011480 Protease Inhibitors
MeSH PA D000084762 Viral Protease Inhibitors
FDA EPC N0000175889 Protease Inhibitor
FDA MoA N0000182141 Cytochrome P450 3A4 Inhibitors
FDA MoA N0000187062 Cytochrome P450 2C8 Inhibitors
FDA MoA N0000190114 Cytochrome P450 3A Inhibitors
FDA MoA N0000191269 UDP Glucuronosyltransferases Inhibitors
FDA MoA N0000191272 UGT1A1 Inhibitors
CHEBI has role CHEBI:35660 HIV protease inhibitors
CHEBI has role CHEBI:36044 antiviral drugs

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Human immunodeficiency virus infection indication 86406008 DOID:526
Prevention of HIV Infection after Exposure off-label use
Hyperbilirubinemia contraindication 14783006 DOID:2741
Hepatic failure contraindication 59927004
Chronic type B viral hepatitis contraindication 61977001
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Hemophilia contraindication 90935002
Lactic acidosis contraindication 91273001 DOID:3650
Kidney stone contraindication 95570007
Chronic hepatitis C contraindication 128302006
Liver function tests abnormal contraindication 166603001
Atrioventricular block contraindication 233917008 DOID:0050820
Disease of liver contraindication 235856003 DOID:409
Breastfeeding (mother) contraindication 413712001




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.91 acidic
pKa2 11.57 acidic
pKa3 4.94 Basic
pKa4 1.0 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 300MG BASE;150MG EVOTAZ BRISTOL-MYERS SQUIBB N206353 Jan. 29, 2015 RX TABLET ORAL 8148374 Sept. 3, 2029 TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Multidrug resistance protein 1 Transporter IC50 4.17 CHEMBL
Cytochrome P450 2C9 Enzyme Ki 4.92 WOMBAT-PK
Cytochrome P450 1A2 Enzyme Ki 4.92 WOMBAT-PK
UDP-glucuronosyltransferase 1-1 Enzyme Ki 5.72 WOMBAT-PK
Cytochrome P450 3A4 Enzyme Ki 5.63 WOMBAT-PK
Pol polyprotein Enzyme INHIBITOR Ki 9.62 CHEMBL CHEMBL
Gag-Pol polyprotein Polyprotein Ki 8.58 WOMBAT-PK
Reverse transcriptase/RNaseH Enzyme IC50 7.59 CHEMBL
Protease Enzyme IC50 8.40 CHEMBL
Protease Unclassified Ki 10.27 CHEMBL
Protease Unclassified Ki 10.12 CHEMBL

External reference:

IDSource
4024316 VUID
N0000022320 NUI
D01276 KEGG_DRUG
229975-97-7 SECONDARY_CAS_RN
343047 RXNORM
C1176383 UMLSCUI
CHEBI:37924 CHEBI
DR7 PDB_CHEM_ID
CHEMBL1163 ChEMBL_ID
CHEMBL1200678 ChEMBL_ID
D000069446 MESH_DESCRIPTOR_UI
DB01072 DRUGBANK_ID
11138 IUPHAR_LIGAND_ID
8181 INN_ID
QZU4H47A3S UNII
148192 PUBCHEM_CID
17380 MMSL
267545 MMSL
30601 MMSL
46998 MMSL
d04882 MMSL
000306 NDDF
000539 NDDF
4021397 VANDF
4024316 VANDF
404838006 SNOMEDCT_US
413591007 SNOMEDCT_US
413592000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
REYATAZ HUMAN PRESCRIPTION DRUG LABEL 1 0003-3622 CAPSULE, GELATIN COATED 300 mg ORAL NDA 29 sections
REYATAZ HUMAN PRESCRIPTION DRUG LABEL 1 0003-3624 CAPSULE, GELATIN COATED 150 mg ORAL NDA 29 sections
REYATAZ HUMAN PRESCRIPTION DRUG LABEL 1 0003-3631 CAPSULE, GELATIN COATED 200 mg ORAL NDA 29 sections
REYATAZ HUMAN PRESCRIPTION DRUG LABEL 1 0003-3638 POWDER 50 mg ORAL NDA 29 sections
EVOTAZ HUMAN PRESCRIPTION DRUG LABEL 2 0003-3641 TABLET 300 mg ORAL NDA 30 sections
EVOTAZ HUMAN PRESCRIPTION DRUG LABEL 2 0003-3641 TABLET 300 mg ORAL NDA 30 sections
Atazanavir Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0093-5526 CAPSULE 150 mg ORAL ANDA 28 sections
Atazanavir Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0093-5526 CAPSULE 150 mg ORAL ANDA 28 sections
Atazanavir Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0093-5527 CAPSULE 200 mg ORAL ANDA 28 sections
Atazanavir Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0093-5527 CAPSULE 200 mg ORAL ANDA 28 sections
Atazanavir Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0093-5528 CAPSULE 300 mg ORAL ANDA 28 sections
Atazanavir Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0093-5528 CAPSULE 300 mg ORAL ANDA 28 sections
Atazanavir Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0904-6875 CAPSULE 300 mg ORAL ANDA 27 sections
Atazanavir Sulfate Human Prescription Drug Label 1 16714-860 CAPSULE 150 mg ORAL ANDA 27 sections
Atazanavir Sulfate Human Prescription Drug Label 1 16714-861 CAPSULE 200 mg ORAL ANDA 27 sections
Atazanavir Sulfate Human Prescription Drug Label 1 16714-862 CAPSULE 300 mg ORAL ANDA 27 sections
Atazanavir HUMAN PRESCRIPTION DRUG LABEL 1 31722-653 CAPSULE 150 mg ORAL ANDA 29 sections
Atazanavir HUMAN PRESCRIPTION DRUG LABEL 1 31722-654 CAPSULE 200 mg ORAL ANDA 29 sections
Atazanavir HUMAN PRESCRIPTION DRUG LABEL 1 31722-655 CAPSULE 300 mg ORAL ANDA 29 sections
Atazanavir Human Prescription Drug Label 1 42385-920 CAPSULE 150 mg ORAL ANDA 27 sections
Atazanavir Human Prescription Drug Label 1 42385-921 CAPSULE 200 mg ORAL ANDA 27 sections
Atazanavir Human Prescription Drug Label 1 42385-922 CAPSULE 300 mg ORAL ANDA 27 sections
Atazanavir Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 51407-171 CAPSULE 150 mg ORAL ANDA 28 sections
Atazanavir Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 51407-172 CAPSULE 200 mg ORAL ANDA 28 sections
Atazanavir Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 51407-173 CAPSULE 300 mg ORAL ANDA 28 sections
REYATAZ HUMAN PRESCRIPTION DRUG LABEL 1 54868-4854 CAPSULE, GELATIN COATED 200 mg ORAL NDA 27 sections
REYATAZ HUMAN PRESCRIPTION DRUG LABEL 1 54868-4857 CAPSULE, GELATIN COATED 150 mg ORAL NDA 27 sections
REYATAZ HUMAN PRESCRIPTION DRUG LABEL 1 54868-5838 CAPSULE, GELATIN COATED 300 mg ORAL NDA 27 sections
Atazanavir Sulfate Human Prescription Drug Label 1 65862-710 CAPSULE 100 mg ORAL ANDA 27 sections
Atazanavir Sulfate Human Prescription Drug Label 1 65862-711 CAPSULE 150 mg ORAL ANDA 27 sections